Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.
Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.
复制标题
新型抗纤维化疗法对特发性肺纤维化中患者结局的影响：患者的选择和观点。
DOI：
10.2147/prom.s144425
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Lee JS
中科院分区：
文献类型：
--
作者：
Graney BA;Lee JS
特发性肺纤维化，一种无法治愈的，进行性纤维化的间质性肺疾病，由于症状，功能性局限性以及补充氧气的限制而产生的生活质量受损。两种抗纤维化药物，nintedanib和pirfenidone，被批准用于治疗特发性肺纤维化。两种药物都降低了肺功能的下降速度，但尚未完全了解它们对患者报告结果的影响。 Nintedanib可能会减慢治疗患者的健康相关生活质量下降。吡非酮可能会减慢呼吸困难的进展并改善咳嗽。考虑到与药物有关的副作用和给药时间表，患者和提供者在开始抗纤维化疗法时应参与共同的决策。尽管抗纤维化疗法可能会影响与健康相关的生活质量，但提供者还应专注于对患者的全面护理，以改善与健康相关的结果。这包括多学科评估，合并症的诊断和治疗，以及参与并参与肺部康复计划。
Patients with idiopathic pulmonary fibrosis, an incurable, progressive fibrotic interstitial lung disease, suffer an impaired quality of life due to symptoms, resultant functional limitations, and the constraints of supplemental oxygen. Two antifibrotic medications, nintedanib and pirfenidone, are approved for the treatment of idiopathic pulmonary fibrosis. Both medications slow the rate of decline of lung function, but their effect on patient-reported outcomes is not yet fully understood. Nintedanib may slow the decline in health-related quality of life for treated patients. Pirfenidone may slow the progression of dyspnea and improve cough. Patients and providers should participate in shared decision-making when starting antifibrotic therapy, taking into consideration the benefits of treatment in addition to drug-related side effects and dosing schedules. Although antifibrotic therapy may have an impact on health-related quality of life, providers should also focus on comprehensive care of the patient to improve health-related outcomes. This includes a multidisciplinary evaluation, diagnosis and treatment of comorbid medical conditions, and referral to and participation in a pulmonary rehabilitation program.